Retired
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
What's important is that the FDA and regulatory bodies agree, not a "med school lecturer" right?
"They" be crafty and well versed this time around I wonder when chatGPT takes over?
So Rett criticisms are now disgustingly boiled down to... there aren't ENOUGH sick children out there.
If I recall correctly, mine were taxed and near the highest rate...ooph. Rich people problems.
BTW, all of this activity will generate form 4's and if cashless will include $AVXL stock sales. Right? Maybe some directors can open market buy to improve the optics.
RSBQ-AUC simply makes more sense to me.
The Rett community will soon have trofinetide to try, but with the known adverse effects, and can start to look forward to soon using blarcamesine. Great news for the Rett community.
On the rare disease front, Fragile X syndrome will be next... I hear it's "right around the corner"
Surprise, surprise, one of the hedge funds what was successful, Citadel, also happens to be where the majority of our dark pool retail order flow goes through...
I'm waiting for the Netflix special on this time period of equity market history.
Payment for order flow, market maker exceptions and deficiencies in back end operational clearing by the DTCC, make for some conspiracy level shit that even I'm starting to believe there is market manipulation afoot.
Hedge fund managers are often just big gamblers with others people's money.
I frankly love watching a cocky strategy, that often relies on extreme leverage, collapse and fail in spectacular fashion.
That's a Covered Put with a collar. Short stock, short put and the addition of the a long put creates a the collar.
Some folks are getting downright aggressive buying through the ASK levels... hmmmm....
Strong enrollment numbers for their Parkinson disease trial with the possibility of Q2 interim analysis is what's driving $ANVS combined with a tiny number of outstanding shares.
I own it, but don't have any understanding of its MOA.
Very unlike the study time I've put into sigmar1 and muscarinic modulation and $AVXL.
No luck needed.
Academic discoveries in S1R science are starting to roll out with regularity, and soon corporate trial data from Alzheimer's disease, Rett Disease, and Parkinson's Disease Dementia will confirm the academic theories.
Patience, not luck is required.
Ahh yes, I remember my first stock option exercise...and the taxes...
Keep that negative spin going and be prepared to mention Dr. Missing's expiring 7/5/2023 stock option grant with an exercise value of $1.60 for 500,000 shares in the dilution schtick.
LOL..."Odds ratios" That's what the new hire is for.
I've been a biotech investor and trader a long time, the "research front" definitely can move the PPS.
The plan has always been solid and it better today than it's ever been, it's been the timing that's been off.
Rare diseases along with indication expansion based upon S1R and muscarinic receptors will be the focus on the research front.
I think Rett syndrome will be the first indication to market.
Good explanation of the "titration paradox". No bias to it, it is what it is
I had been wondering how the heck does a company separate out the cohorts when dosage changes are involved?
It makes perfect sense to me. So some realistic scenarios for the Alzheimer's indication could be granting of accelerated approval with a requisite P4 for more data, or more likely is another P3 conducted with the assistance of a large partner firm.
Switching gears to the rare disease Rett Syndrome indication, I doubt additional trials will be needed prior to a NDA submission.
Notice the verb tense of my statement... "to put out" future tense.
First off, I didn't say "withdraw the CTAD presentation", you did.
Second I'm referring to producing a NEW for public consumption report that includes the hastily prepared CTAD presentation.
Yep and in the meantime the stock will follow tradable levels any unemotional trader can profit from.
Really, it's "The only explanation I can think of"... how about maybe Anavex wants to put of a fully analyzed report versus the on they presented at CTAD.
I've said this before and I'll say it again $AVXL is not the type of company that cares to placate retail investor whims.
Right, maybe it could hasten sleep onset and then also have a positive effect on REM.
So true, as any dementia caretaker will tell you, sleep is a serious challenge and patients don't stick to schedules.
I hope the fully analyzed PDD trial data provides more data on how blarcamesine improved sleep. It was hinted at this far, but improving sleep and sleep cycles is a MAJOR win from a caretakers perspective.
There are more reasons to stay invested, and even more reasons to start an investment in $AVXL than ever before, "even if the outcome is most likely a next P3 Precision Medicine trial based on clearly understood responder characteristics."
BTW, I'm enjoying the highlighting of uncertainty (incomplete trial read out) to foment doubt and incite fear as it keeps it interesting and motivates trading activity.
Totally agree that commercialization of blarcamesine refers to both AD and Rett syndrome.
The context of my comment was around the comment which BP's did Dr.M "negotiate with" and in my mind Rett will be handled completely in-house, thus no negotiations needed. While on the AD indication we all know a BP partner will be sought for commercialization .
Anaxex has made it explicitly clear they are ready to move from research to commercialization on Alzheimer's disease. It will be curious to see who else is ready?
Market systems can be volatile. I've always prefered the term "order imbalance" versus "manipulation".
Some of us are adept at reading these imbalances and become successful traders, others not so much.
I retired early too thanks to being able to read market patterns.
That will be awesome.
$AVXL unfortunately plants is own seeds of FUD by creating uncertainty and doubt with it's readouts.
$12.05 was the close not $11.77, so $12 assignment was just normal.
You were assigned on your $12 out of the money covered call write? That is odd.
Creditors will decide what to do with the "assets" as bankruptcy is not an option for marijuana companies and common equity is worthless.
Current assets = 7.21 million and current liabilities = 75.0 million
Assets = 54 million and liabilities = 96 million
My guess is all operations will cease and the company will be dissolved. The remaining assets will be transferred to a new corporate entity owned by the creditors.
$AVXL follows good accounting principles and has never received a warning letter. How does your non sequitur about the SEC apply to Anavex planning of the FXS trial?
If the FDA was faster in granting Fragile X Orphan Drug Status the trial would have already been in progress.
https://www.anavex.com/post/us-fda-orphan-drug-designation-to-anavex-2-73-blarcamesine-for-the-treatment-of-fragile-x-syndrome
I'll take good planning over hasty actions any day.
A Top Line Readout required zero analysis from Ariana.
I assure you there will be multiple subgroup analytics from the AD 2b/3 trial.
Thanks for inserting the FUD lately it helps accumulators like myself.
My biotech track record was worse, yet the few I predicted correctly enabled me to retire early.
Taking calculated risk has always been one of my "mantra's"
Novel approaches such as Sigma 1R modulation is an "idea with no precedence."